Candriam S.C.A. Has $1.21 Million Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Candriam S.C.A. reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,302 shares of the medical equipment provider’s stock after selling 7,513 shares during the period. Candriam S.C.A.’s holdings in Zimmer Biomet were worth $1,213,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Brighton Jones LLC acquired a new position in Zimmer Biomet during the fourth quarter worth $204,000. CWM LLC increased its position in shares of Zimmer Biomet by 2.3% during the 1st quarter. CWM LLC now owns 8,078 shares of the medical equipment provider’s stock worth $914,000 after purchasing an additional 180 shares in the last quarter. Wealthfront Advisers LLC increased its position in shares of Zimmer Biomet by 37.1% during the 1st quarter. Wealthfront Advisers LLC now owns 3,803 shares of the medical equipment provider’s stock worth $430,000 after purchasing an additional 1,030 shares in the last quarter. Cullen Frost Bankers Inc. lifted its holdings in Zimmer Biomet by 1,452.4% during the 1st quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares during the last quarter. Finally, Private Advisor Group LLC boosted its position in Zimmer Biomet by 1.4% in the first quarter. Private Advisor Group LLC now owns 14,079 shares of the medical equipment provider’s stock valued at $1,593,000 after buying an additional 200 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Down 1.3%

ZBH stock opened at $88.72 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.72. The company has a market cap of $17.58 billion, a P/E ratio of 21.59, a PEG ratio of 2.29 and a beta of 0.67. The business has a fifty day moving average of $98.24 and a 200-day moving average of $96.93.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period last year, the company earned $1.74 earnings per share. The company’s revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Sunday. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Barclays lowered their target price on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research note on Wednesday, November 5th. Finally, BTIG Research reduced their price target on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $109.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.